Globenewswireยท2025-09-17 11:00Core Insights - Nurix Therapeutics announced the presentation of preclinical data for GS-6791, a novel IRAK4 protein degrader, which supports its advancement into clinical studies [1][2] - The findings were presented at the European Academy of Dermatology and Venereology (EADV) Congress, highlighting the potential of GS-6791 in treating inflammatory diseases [1][4] Preclinical Data - GS-6791 mediates sustained degradation of IRAK4, leading to significant inhibition of IL-1 and IL-36-driven responses in skin epithelial cell systems [2][5] - The drug demonstrated near-complete knockdown of IRAK4 in human blood and keratinocytes, with deep inhibition of cytokine pathways relevant to dermatologic diseases [5] Mechanism of Action - GS-6791 is characterized as a potent, orally available degrader of IRAK4, providing a differentiated pharmacologic profile compared to traditional kinase inhibitors [3][4] - By selectively degrading IRAK4, GS-6791 targets complex immune signaling pathways, potentially expanding treatment options for patients with inflammatory diseases [3][4] Collaboration with Gilead - Nurix and Gilead Sciences entered a strategic collaboration in June 2019 to develop targeted protein degradation therapies, with Nurix receiving $135 million to date [4] - For the IRAK4 program, Nurix is eligible for up to $420 million in potential milestone payments and royalties on net sales, with co-development options available for two programs in the U.S. [4][5] Clinical Development - Gilead exercised its option to license GS-6791 in March 2023, taking responsibility for further development [5] - The Investigational New Drug (IND) application for GS-6791 was cleared by the FDA in April 2025, with an ongoing Phase 1 trial assessing safety and pharmacodynamics in healthy volunteers [5]